Home LiteratureArticle Details
PMID: 19267917 Published · epublish English Journal Article

The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.

BMC cancer ·Vol. 9 ·2009-03-06 ·Pages 78

Grimm C, Kantelhardt E, Heinze G, Polterauer S, Zeillinger R, Kölbl H, Reinthaller A, Hefler L

Abstract

The proinflammatory cytokine interleukin-1 (IL-1) is known to play an important role in the carcinogenesis of breast cancer. Although IL-1 gene polymorphisms were reported to be associated with increased risk of breast cancer, their influence on survival of Caucasian breast cancer patients remains to be shown. We studied the influence of four common gene polymorphisms (IL1A -889C/T, IL1B -511C/T, IL1B +3953E1/E2, and IL1RN long/2) of the IL-1 family on survival in 262 Caucasian patients with breast cancer by univariate and multivariate survival analysis. The combined effect of the four gene polymorphisms on overall survival was studied by haplotype analysis. In the present study 38 cases of cancer related death and a median time of follow-up (range) of 55.3 (0.4-175.8) months was observed. IL1RN 2/2 (homozygous mutant) gene polymorphism was associated with shortened disease free and overall survival in a univariate (p = 0.001 and p = 0.01, respectively) and multivariate analysis (p = 0.002, Odds Ratio [95% Confidence Interval] = 3.6 [1.6-8.0] and p = 0.05, Odds Ratio = 3.0 [1.1-9.3], respectively). Presence of the homozygous mutant genotype of the IL1A -889 and IL1B +3953 gene polymorphism was associated with overall survival in the univariate (p = 0.004 and p = 0.002, respectively), but not in the multivariate analysis. No association was observed between all possible haplotype combinations and overall survival. Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.

MeSH Terms
Alleles Breast Neoplasms/ethnology,genetics Disease-Free Survival Female Humans Interleukin 1 Receptor Antagonist Protein/genetics Interleukin-1/genetics Middle Aged Polymorphism, Genetic Whites
Chemicals
IL1RN protein, human Interleukin 1 Receptor Antagonist Protein Interleukin-1
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Grimm Christoph
Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria. christoph.grimm@meduniwien.ac.at
Kantelhardt Eva
Heinze Georg
Polterauer Stephan
Zeillinger Robert
Kölbl Heinz
Reinthaller Alexander
Hefler Lukas
References (32)
32 references, click to expand
  1. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development.
    FASEB J. 2004 Jan;18(1):161-3 PMID: 14597552
  2. Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer.
    Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1205-8 PMID: 14652282
  3. Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population.
    Int J Cancer. 2006 May 15;118(10):2554-8 PMID: 16358261
  4. Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer.
    Biochem Biophys Res Commun. 2000 Aug 18;275(1):60-2 PMID: 10944441
  5. IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas.
    Clin Cancer Res. 2001 Jun;7(6):1812-20 PMID: 11410524
  6. A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis.
    Gynecol Oncol. 2004 Mar;92(3):936-40 PMID: 14984963
  7. Interleukin-1 beta enhances interleukin-1 receptor antagonist content in human somatotroph adenoma cell cultures.
    J Clin Endocrinol Metab. 1998 Jul;83(7):2429-34 PMID: 9661623
  8. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro.
    Eur J Clin Invest. 1992 Jun;22(6):396-402 PMID: 1353022
  9. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk.
    Br J Cancer. 2005 Aug 22;93(4):493-7 PMID: 16106254
  10. Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women.
    Clin Cancer Res. 2005 Aug 15;11(16):5718-21 PMID: 16115908
  11. Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma.
    Hum Immunol. 2006 Jan-Feb;67(1-2):13-21 PMID: 16698420
  12. Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women.
    Breast Cancer Res Treat. 2006 Mar;96(2):197-202 PMID: 16319982
  13. Molecular analysis of constitutive IL-1alpha gene expression in human melanoma cells: autocrine stimulation through NF-kappaB activation by endogenous IL-1alpha.
    Cytokine. 1998 Nov;10(11):872-9 PMID: 9878124
  14. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene.
    Lung Cancer. 2005 Dec;50(3):285-90 PMID: 16126303
  15. Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines.
    Breast Cancer Res Treat. 2003 May;79(2):253-63 PMID: 12825860
  16. Anakinra.
    BioDrugs. 2002;16(4):303-11; discussion 313-4 PMID: 12196041
  17. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals.
    Eur Cytokine Netw. 2000 Jun;11(2):251-5 PMID: 10903804
  18. Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity.
    Int J Gynecol Cancer. 2006;16 Suppl 2:556-9 PMID: 17010072
  19. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis.
    Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2394-400 PMID: 11073843
  20. Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population.
    Am J Gastroenterol. 2005 Sep;100(9):1941-8 PMID: 16128937
  21. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist.
    Int Rev Immunol. 1998;16(5-6):457-99 PMID: 9646173
  22. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
    Cancer. 2004 Apr 1;100(7):1388-96 PMID: 15042672
  23. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype.
    Br J Cancer. 2004 Jan 26;90(2):419-22 PMID: 14735187
  24. Biologic basis for interleukin-1 in disease.
    Blood. 1996 Mar 15;87(6):2095-147 PMID: 8630372
  25. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat.
    Hum Genet. 1993 May;91(4):403-4 PMID: 8500797
  26. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype.
    Clin Cancer Res. 2003 Oct 15;9(13):4877-83 PMID: 14581361
  27. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.
    Eur Cytokine Netw. 2005 Dec;16(4):253-60 PMID: 16464738
  28. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta).
    Hum Mol Genet. 1992 Sep;1(6):450 PMID: 1301918
  29. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice.
    Cancer Res. 2003 Sep 15;63(18):5957-61 PMID: 14522922
  30. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism.
    Clin Exp Immunol. 1995 Feb;99(2):303-10 PMID: 7851026
  31. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist.
    Cancer Invest. 2000;18(4):293-302 PMID: 10808364
  32. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.
    Eur J Immunogenet. 2004 Aug;31(4):167-73 PMID: 15265021
Article Info
Journal
BMC cancer
Abbr.
BMC Cancer
ISSN
1471-2407
Published
2009-03-06
Epub
2009-00-06
Pages
78
Language
English
Region
England
NLM ID
100967800
PMCID
PMC2656545
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com